Relay Therapeutics (RLAY, $6.37) is predicted by A.I.dvisor to decline by to $6.12 or more within the next month. Keeping in mind similar previously-analyzed scenarios where the stock trended down during the month, the odds of a Downtrend continuation are
a clinical-stage precision medicines company, which focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets